Table 8.
High Serum Anti-PGL-I Antibody Titer and in Situ Detection of PGL-I and Viable Ml. Bacilli in Skin Biopsy Specimen of Untreated Leprosy Patients and in Those in the Course of the Disease
| Untreated patients | Follow-up | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Classification | Patient number | BI | αPGL-I* | PGL-I† | Ml. RNA‡ | Treatment status | BI | αPGL-I* | PGL-I† | Ml. RNA‡ |
| TT | CPB05 | 0 | − | − | + | RFT | 0 | − | − | − |
| TT | R90-36 | 0 | ND | − | + | ND | ||||
| BT | R91-18 | 0 | − | − | + | RFT | 0 | − | − | − |
| BT | R92-24 | 0 | − | − | − | RFT | 0 | − | − | − |
| BT | R92-11 | 0 | − | − | − | ND | ||||
| BT | R87-60 | 0 | + | + | ++ | ND | ||||
| BT | R88-14 | 0 | − | + | + | ND | ||||
| BL | R91-19 | 4+ | + | + | +++ | ND | ||||
| BB | R92-33 | 4+ | − | + | +++ | On treatment (1 year) | 1+ | − | + | + |
| BL | R90-18 | ND | ND | ND | ND | RFT | 0 | + | + | − |
| BL | R88-4 | 4+ | + | + | +++ | RFT | 0 | − | − | − |
| BL | R89-81 | 4+ | − | + | +++ | RFT | 1+ | − | + | − |
| BL | R90-32 | ND | ND | ND | ND | RFT | 0 | + | + | +§ |
| BL | R89-121 | 5+ | + | + | − | RFT | 0 | + | + | − |
| BL | R90-21 | 4+ | + | + | +++ | RFT | 0 | + | + | − |
| BL | R88-1 | ND | ND | ND | ND | RFT | 1+ | + | + | ++¶ |
| RFT | 0 | + | + | − |
RFT, released from treatment; other abbreviations (TT, BT and BL) are as in Table 1▶ .
*Anti-PGL-I antibody titer in serum was measured by ELISA; serum values were considered high with OD >0.500.
†PGL-I is detected by immunohistochemical analysis using MAb DZ-1.
‡Ml. RNA was detected by NASBA.
§Patient with poor compliance of therapy.
¶Patient was investigated for possible relapse.